Dicerna Pharmaceuticals Initiates Phase 1 Study of DCR-MYC By: Benzinga via Benzinga April 16, 2014 at 16:18 PM EDT Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced the initiation of ... Read More >> Related Stocks: Dicerna Pharmaceutic